ERBB2 and prostate adenocarcinoma: In prostate adenocarcinomas, the role of HER2/neu is controversial, mainly because of technical problems related to the immunohistochemistry method.5,6 Determining of the role of HER2/neu has been a matter of interest since the report of Visakorpi suggesting that hormone-independent tumors switch signaling from the androgen receptor to the HER2/neu receptor.7